Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 16 articles: HTML format

Single Articles

October 2025
1. CHAPMAN PB, Wolchok JD
   Changing Role of Adjuvant Therapy in Stage III Melanoma.
   N Engl J Med. 2025 Oct 18. doi: 10.1056/NEJMe2514054.
   PubMed    
   
   
   
2. ASCIERTO PA, Del Vecchio M, Merelli B, Gogas H, et al
   Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
   N Engl J Med. 2025 Oct 18. doi: 10.1056/NEJMoa2504966.
   PubMed     Abstract available
   
   
   September 2025
3. PASCH M, Tutein Nolthenius J
   Hutchinson's Sign in Subungual Melanoma In Situ.
   N Engl J Med. 2025;393:e13.
   PubMed    
   
   
   March 2025
4. WOLCHOK JD, Hodi FS, Larkin J
   Nivolumab plus Ipilimumab in Advanced Melanoma. Reply.
   N Engl J Med. 2025;392:1246.
   PubMed    
   
   
   
5. SANTHOSH A
   Nivolumab plus Ipilimumab in Advanced Melanoma.
   N Engl J Med. 2025;392:1245-1246.
   PubMed    
   
   
   January 2025
6. CURTI BD
   Checkpoint Immunotherapy for Melanoma - Offering Hope for Cure.
   N Engl J Med. 2025;392:81-82.
   PubMed    
   
   
   September 2024
7. RUBIN EJ, Yeku OO, Morrissey S
   NEJM at ESMO - Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
   N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMe2411489.
   PubMed    
   
   
   
8. WOLCHOK JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, et al
   Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
   N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2407417.
   PubMed     Abstract available
   
   
   June 2024
9. LONG GV, Hauschild A, Santinami M, Kirkwood JM, et al
   Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
   N Engl J Med. 2024 Jun 19. doi: 10.1056/NEJMoa2404139.
   PubMed     Abstract available
   
   
   
10. BLANK CU, Lucas MW, Scolyer RA, van de Wiel BA, et al
    Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
    N Engl J Med. 2024 Jun 2. doi: 10.1056/NEJMoa2402604.
    PubMed     Abstract available
    
    
    January 2024
11. MOHAREB AM, Kang J, Montazeri K, Shroff SG, et al
    Case 2-2024: A 57-Year-Old Woman with Melanoma and Fever.
    N Engl J Med. 2024;390:255-265.
    PubMed    
    
    
    October 2023
12. HASSEL JC, Piperno-Neumann S, Rutkowski P, Baurain JF, et al
    Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
    N Engl J Med. 2023 Oct 21. doi: 10.1056/NEJMoa2304753.
    PubMed     Abstract available
    
    
    May 2023
13. WEN L, Cai L
    Primary Diffuse Meningeal Melanomatosis.
    N Engl J Med. 2023;388:1892.
    PubMed    
    
    
    March 2023
14. ROHAAN MW, Kessels R, Haanen JBAG
    Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma. Reply.
    N Engl J Med. 2023;388:859-860.
    PubMed    
    
    
    
15. LIM AR, Shin SW
    Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma.
    N Engl J Med. 2023;388:859.
    PubMed    
    
    
    
16. PATEL SP, Othus M, Chen Y, Wright GP Jr, et al
    Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
    N Engl J Med. 2023;388:813-823.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.